How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns

被引：37

作者：

Mazepa, Marshall A. ^{[1
]}

Masias, Camila ^{[2
]}

Chaturvedi, Shruti ^{[3
]}

机构：

[1] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA

[2] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA

[3] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, 720 Rutland Ave,Ross Res Bldg,Room 1025, Baltimore, MD 21205 USA

来源：

BLOOD | 2019年 / 134卷 / 05期

关键词：

THROMBOTIC THROMBOCYTOPENIC PURPURA; PLASMA-EXCHANGE; ANTIBODY DEPLETION; ADAMTS13; ACTIVITY; RITUXIMAB; MICROANGIOPATHIES; BORTEZOMIB; EXPERIENCE; REMISSION; SAFETY;

D O I：

10.1182/blood.2019000954

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor-platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.

引用

页码：415 / 420

页数：6

共 40 条

[1] IMPROVED SURVIVAL IN THROMBOTIC THROMBOCYTOPENIC PURPURA HEMOLYTIC UREMIC SYNDROME - CLINICAL-EXPERIENCE IN 108 PATIENTS [J].

BELL, WR ;

BRAINE, HG ;

NESS, PM ;

KICKLER, TS .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (06) :398-403

[2] Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study [J].

Bendapudi, Pavan K. ;

Hurwitz, Shelley ;

Fry, Ashley ;

Marques, Marisa B. ;

Waldo, Stephen W. ;

Li, Ang ;

Sun, Lova ;

Upadhyay, Vivek ;

Hamdan, Ayad ;

Brunner, Andrew M. ;

Gansner, John M. ;

Viswanathan, Srinivas ;

Kaufman, Richard M. ;

Uhl, Lynne ;

Stowell, Christopher P. ;

Dzik, Walter H. ;

Makar, Robert S. .

LANCET HAEMATOLOGY, 2017, 4 (04) :E157-E164

[3] Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center [J].

Benhamou, Y. ;

Boelle, P-Y ;

Baudin, B. ;

Ederhy, S. ;

Gras, J. ;

Galicier, L. ;

Azoulay, E. ;

Provot, F. ;

Maury, E. ;

Pene, F. ;

Mira, J. -P. ;

Wynckel, A. ;

Presne, C. ;

Poullin, P. ;

Halimi, J. -M. ;

Delmas, Y. ;

Kanouni, T. ;

Seguin, A. ;

Mousson, C. ;

Servais, A. ;

Bordessoule, D. ;

Perez, P. ;

Hamidou, M. ;

Cohen, A. ;

Veyradier, A. ;

Coppo, P. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (02) :293-302

[4] Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience [J].

Benhamou, Ygal ;

Assie, Cyrielle ;

Boelle, Pierre-Yves ;

Buffet, Marc ;

Grillberger, Rana ;

Malot, Sandrine ;

Wynckel, Alain ;

Presne, Claire ;

Choukroun, Gabriel ;

Poullin, Pascale ;

Provot, Francois ;

Gruson, Didier ;

Hamidou, Mohamed ;

Bordessoule, Dominique ;

Pourrat, Jacques ;

Mira, Jean-Paul ;

Le Guern, Veronique ;

Pouteil-Noble, Claire ;

Daubin, Cedric ;

Vanhille, Philippe ;

Rondeau, Eric ;

Palcoux, Jean-Bernard ;

Mousson, Christiane ;

Vigneau, Cecile ;

Bonmarchand, Guy ;

Guidet, Bertrand ;

Galicier, Lionel ;

Azoulay, Elie ;

Rottensteiner, Hanspeter ;

Veyradier, Agnes ;

Coppo, Paul .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (08) :1181-1186

[5] Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura [J].

Cataland, Spero R. ;

Kourlas, Peter J. ;

Yang, Shangbin ;

Geyer, Susan ;

Witkoff, Leslie ;

Wu, Haiwa ;

Masias, Camila ;

George, James N. ;

Wu, Haifeng M. .

BLOOD ADVANCES, 2017, 1 (23) :2075-2082

[6] Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab [J].

Chemnitz, J ;

Draube, A ;

Scheid, C ;

Staib, P ;

Schulz, A ;

Diehl, V ;

Söhngen, D .

AMERICAN JOURNAL OF HEMATOLOGY, 2002, 71 (02) :105-108

[7] A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab [J].

Clark, William F. ;

Rock, Gail ;

Barth, David ;

Arnold, Donald M. ;

Webert, Kathyrn E. ;

Yenson, Paul R. ;

Kelton, John G. ;

Li, Lihua ;

Foley, Steven R. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (02) :208-217

[8] Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura [J].

Eskazan, Ahmet Emre .

ANNALS OF HEMATOLOGY, 2016, 95 (11) :1751-1756

[9] Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story [J].

Froissart, Antoine ;

Veyradier, Agnes ;

Hie, Miguel ;

Benhamou, Ygal ;

Coppo, Paul .

EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2015, 26 (09) :659-665

[10] Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center [J].

Froissart, Antoine ;

Buffet, Marc ;

Veyradier, Agnes ;

Poullin, Pascale ;

Provot, Francois ;

Malot, Sandrine ;

Schwarzinger, Michael ;

Galicier, Lionel ;

Vanhille, Philippe ;

Vernant, Jean-Paul ;

Bordessoule, Dominique ;

Guidet, Bertrand ;

Azoulay, Elie ;

Mariotte, Eric ;

Rondeau, Eric ;

Mira, Jean-Paul ;

Wynckel, Alain ;

Clabault, Karine ;

Choukroun, Gabriel ;

Presne, Claire ;

Pourrat, Jacques ;

Hamidou, Mohamed ;

Coppo, Paul .

CRITICAL CARE MEDICINE, 2012, 40 (01) :104-111

← 1 2 3 4 →